“The existing condition has uncovered some structural weaknesses during the EU’s medicines source chain and also a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides claimed. She recommended that supply chain issues be tackled in an EU pharmaceutical system anticipated being released by